{"protocolSection": {"identificationModule": {"nctId": "NCT00044655", "orgStudyIdInfo": {"id": "GCO 98-924"}, "secondaryIdInfos": [{"id": "R01MH059312", "type": "NIH", "link": "https://reporter.nih.gov/quickSearch/R01MH059312"}], "organization": {"fullName": "Icahn School of Medicine at Mount Sinai", "class": "OTHER"}, "briefTitle": "Switching Medication to Treat Schizophrenia", "officialTitle": "Effectiveness of Switching Antipsychotic Medications"}, "statusModule": {"statusVerifiedDate": "2016-03", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2001-07"}, "primaryCompletionDateStruct": {"date": "2009-03", "type": "ACTUAL"}, "completionDateStruct": {"date": "2009-03", "type": "ACTUAL"}, "studyFirstSubmitDate": "2002-09-03", "studyFirstSubmitQcDate": "2002-09-04", "studyFirstPostDateStruct": {"date": "2002-09-05", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2013-09-27", "resultsFirstSubmitQcDate": "2013-09-30", "resultsFirstPostDateStruct": {"date": "2013-12-05", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2016-03-28", "lastUpdatePostDateStruct": {"date": "2016-04-28", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Icahn School of Medicine at Mount Sinai", "class": "OTHER"}, "collaborators": [{"name": "National Institute of Mental Health (NIMH)", "class": "NIH"}]}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "This study will evaluate the effectiveness of switching medications in decreasing schizophrenia symptoms in individuals who are currently taking an antipsychotic medication for the treatment of schizophrenia.", "detailedDescription": "Over the past several years, new, \"atypical\" antipsychotic medications have become available to treat schizophrenia with little information to guide prescribing for relatively stable outpatients.\n\nParticipants will be randomly assigned to either continue taking their current medications for schizophrenia, or to switch to a new medication. Participants assigned to switch to a new medication will begin receiving either olanzapine (Zyprexa), risperidone (Risperdal), ziprasidone (Geodon), quetiapine (Seroquel), or aripiprazole (Abilify), depending on what they are currently taking. Participants currently taking a single oral medication will switch to olanzapine, risperidone, ziprasidone, quetiapine, or aripiprazole. Participants currently taking a single conventional injectable will begin taking long-acting injectable risperidone (Risperdal Consta). Participants currently taking two antipsychotic medications will begin taking only one of the medications they are currently using. Participants will stay on their assigned treatment for 6 months, after which time the participant's prescribing psychiatrist will advise the participant on which medication should be used. Study participants are interviewed at study start and at follow-up visits for 1 year."}, "conditionsModule": {"conditions": ["Schizophrenia"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "SINGLE", "whoMasked": ["OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 219, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Stay on baseline medication prescribed", "type": "ACTIVE_COMPARATOR", "description": "Participants will continue taking medication prescribed at study entry: 1) either long-acting injectable haloperidol or fluphenazine, OR 2) two antipsychotic medications which might include a combination of any of the following: risperidone, olanzapine, ziprasidone, quetiapine, aripiprazole, or conventional (typical) antipsychotic medications.", "interventionNames": ["Drug: Risperidone", "Drug: Olanzapine", "Drug: Ziprasidone", "Drug: Quetiapine", "Drug: Aripiprazole"]}, {"label": "Switch per study protocol", "type": "ACTIVE_COMPARATOR", "description": "Participants will change medications from medication prescribed at study entry, either: 1) long-acting injectable risperidone, OR 2) one of the two antipsychotic medications prescribed at baseline which may include any of the following: risperidone, olanzapine, ziprasidone, quetiapine, aripiprazole, or conventional (typical) antipsychotic medications.", "interventionNames": ["Drug: Risperidone", "Drug: Olanzapine", "Drug: Ziprasidone", "Drug: Quetiapine", "Drug: Aripiprazole"]}], "interventions": [{"type": "DRUG", "name": "Risperidone", "description": "As prescribed by routine prescriber (not dictated by study protocol)", "armGroupLabels": ["Stay on baseline medication prescribed", "Switch per study protocol"], "otherNames": ["Risperdal, Risperdal Consta"]}, {"type": "DRUG", "name": "Olanzapine", "description": "As prescribed by routine prescriber (not dictated by study protocol)", "armGroupLabels": ["Stay on baseline medication prescribed", "Switch per study protocol"], "otherNames": ["Zyprexa"]}, {"type": "DRUG", "name": "Ziprasidone", "description": "As prescribed by routine prescriber (not dictated by study protocol)", "armGroupLabels": ["Stay on baseline medication prescribed", "Switch per study protocol"], "otherNames": ["Geodon"]}, {"type": "DRUG", "name": "Quetiapine", "description": "As prescribed by routine prescriber (not dictated by study protocol)", "armGroupLabels": ["Stay on baseline medication prescribed", "Switch per study protocol"], "otherNames": ["Seroquel"]}, {"type": "DRUG", "name": "Aripiprazole", "description": "As prescribed by routine prescriber (not dictated by study protocol)", "armGroupLabels": ["Stay on baseline medication prescribed", "Switch per study protocol"], "otherNames": ["Abilify"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Number Who Discontinued Medication Within First 6 Study Months", "timeFrame": "Measured at Six Months"}], "secondaryOutcomes": [{"measure": "Psychiatric Symptoms, Hospitalization, and Medication Side Effects", "timeFrame": "Measured at Year 1"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion criteria:\n\n* SCID diagnosis of schizophrenia or schizoaffective disorder\n* Partially remitted outpatients, defined as persons who have received clear symptomatic benefit from antipsychotic medication but remain symptomatic (due to lack of efficacy or inability to tolerate an efficacious dose) or suffer significant side effects\n* Treatment with antipsychotic medications for at least 2 months\n* Received at least 1 outpatient mental health service every 3 months for the past 6 months\n\nExclusion criteria:\n\n* Severe symptoms or side effects that indicate the necessity for a medication change\n* Currently taking 3 or more antipsychotic medications for ongoing daily administration (PRN medications and mood stabilizers are allowable)\n* Treatment with clozapine\n* One or more nights spent in a psychiatric hospitalization within the past 3 months\n* Received services from a crisis intervention program within the past 3 months\n* Require placement in a skilled nursing facility as a result of a physical condition or disability\n* Criminal charges pending (once charges clear, the person will be considered)\n* Pregnant or breast feeding\n* Contraindication to any of the medications to which the patient might be assigned", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Susan M. Essock, PhD", "affiliation": "Columbia University", "role": "STUDY_CHAIR"}]}, "referencesModule": {"references": [{"pmid": "22480442", "type": "RESULT", "citation": "Covell NH, McEvoy JP, Schooler NR, Stroup TS, Jackson CT, Rojas IA, Essock SM; Schizophrenia Trials Network. Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial. J Clin Psychiatry. 2012 May;73(5):669-75. doi: 10.4088/JCP.11m07074. Epub 2012 Mar 6."}, {"pmid": "21536693", "type": "RESULT", "citation": "Essock SM, Schooler NR, Stroup TS, McEvoy JP, Rojas I, Jackson C, Covell NH; Schizophrenia Trials Network. Effectiveness of switching from antipsychotic polypharmacy to monotherapy. Am J Psychiatry. 2011 Jul;168(7):702-8. doi: 10.1176/appi.ajp.2011.10060908. Epub 2011 May 2."}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Stay", "description": "Participants will continue taking medication prescribed at study entry"}, {"id": "FG001", "title": "Switch", "description": "Participants will change medications from medication prescribed at study entry"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "102"}, {"groupId": "FG001", "numSubjects": "117"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "82"}, {"groupId": "FG001", "numSubjects": "79"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "20"}, {"groupId": "FG001", "numSubjects": "38"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Stay", "description": "Participants will continue taking medication prescribed at study entry"}, {"id": "BG001", "title": "Switch", "description": "Participants will change medications from medication prescribed at study entry"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "102"}, {"groupId": "BG001", "value": "117"}, {"groupId": "BG002", "value": "219"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "96"}, {"groupId": "BG001", "value": "112"}, {"groupId": "BG002", "value": "208"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "11"}]}]}]}, {"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "46.9", "spread": "10.4"}, {"groupId": "BG001", "value": "47.7", "spread": "11.3"}, {"groupId": "BG002", "value": "46.9", "spread": "11.0"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "42"}, {"groupId": "BG001", "value": "31"}, {"groupId": "BG002", "value": "73"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "60"}, {"groupId": "BG001", "value": "86"}, {"groupId": "BG002", "value": "146"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "102"}, {"groupId": "BG001", "value": "117"}, {"groupId": "BG002", "value": "219"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Number Who Discontinued Medication Within First 6 Study Months", "populationDescription": "intent to treat samples for 2 substudies: injectable to injectable and polypharmacy to monotherapy", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Measured at Six Months", "groups": [{"id": "OG000", "title": "Stay", "description": "Participants will continue taking medication prescribed at study entry"}, {"id": "OG001", "title": "Switch", "description": "Participants will change medications from medication prescribed at study entry"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "92"}, {"groupId": "OG001", "value": "97"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "23"}]}]}]}, {"type": "SECONDARY", "title": "Psychiatric Symptoms, Hospitalization, and Medication Side Effects", "reportingStatus": "NOT_POSTED", "timeFrame": "Measured at Year 1"}]}, "adverseEventsModule": {"frequencyThreshold": "0", "eventGroups": [{"id": "EG000", "title": "Stay", "description": "Participants will continue taking medication prescribed at study entry", "seriousNumAffected": 0, "seriousNumAtRisk": 102, "otherNumAffected": 0, "otherNumAtRisk": 102}, {"id": "EG001", "title": "Switch", "description": "Participants will change medications from medication prescribed at study entry", "seriousNumAffected": 2, "seriousNumAtRisk": 117, "otherNumAffected": 0, "otherNumAtRisk": 117}], "seriousEvents": [{"term": "Psychiatric Hospitalization", "organSystem": "Psychiatric disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Following medication change, participant's prescriber called Project Director to report that the participant was not doing well and was hospitalized subsequent to symptom exacerbation; prescriber changed client's antipsychotic medication regime.", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 102}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 117}]}, {"term": "Death", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Site PI learned that the 69 year old participant had died following recurrent episodes of bleeding from cerebral aneurism that was diagnosed, but unknown to the site PI, prior to study enrollment (randomized to injectable risperidone)", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 102}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 117}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Nancy H. Covell, Ph.D.", "organization": "NYSPI", "email": "covelln@nyspi.columbia.edu", "phone": "6469450227"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-26", "removedCountries": ["United States"]}, "conditionBrowseModule": {"meshes": [{"id": "D000012559", "term": "Schizophrenia"}], "ancestors": [{"id": "D000019967", "term": "Schizophrenia Spectrum and Other Psychotic Disorders"}, {"id": "D000001523", "term": "Mental Disorders"}], "browseLeaves": [{"id": "M15376", "name": "Schizophrenia", "asFound": "Schizophrenia", "relevance": "HIGH"}, {"id": "M4815", "name": "Mental Disorders", "relevance": "LOW"}, {"id": "M14473", "name": "Psychotic Disorders", "relevance": "LOW"}, {"id": "M21838", "name": "Schizophrenia Spectrum and Other Psychotic Disorders", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BXM", "name": "Behaviors and Mental Disorders"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000077152", "term": "Olanzapine"}, {"id": "D000018967", "term": "Risperidone"}, {"id": "D000068180", "term": "Aripiprazole"}, {"id": "D000069348", "term": "Quetiapine Fumarate"}, {"id": "C000092292", "term": "Ziprasidone"}], "ancestors": [{"id": "D000012702", "term": "Serotonin Antagonists"}, {"id": "D000018490", "term": "Serotonin Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000014150", "term": "Antipsychotic Agents"}, {"id": "D000014149", "term": "Tranquilizing Agents"}, {"id": "D000002492", "term": "Central Nervous System Depressants"}, {"id": "D000011619", "term": "Psychotropic Drugs"}, {"id": "D000018492", "term": "Dopamine Antagonists"}, {"id": "D000015259", "term": "Dopamine Agents"}, {"id": "D000000932", "term": "Antiemetics"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000005765", "term": "Gastrointestinal Agents"}, {"id": "D000017367", "term": "Selective Serotonin Reuptake Inhibitors"}, {"id": "D000014179", "term": "Neurotransmitter Uptake Inhibitors"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000000928", "term": "Antidepressive Agents"}, {"id": "D000018491", "term": "Dopamine Agonists"}, {"id": "D000058825", "term": "Serotonin 5-HT1 Receptor Agonists"}, {"id": "D000017366", "term": "Serotonin Receptor Agonists"}, {"id": "D000058830", "term": "Serotonin 5-HT2 Receptor Antagonists"}, {"id": "D000065127", "term": "Dopamine D2 Receptor Antagonists"}], "browseLeaves": [{"id": "M16904", "name": "Antipsychotic Agents", "relevance": "LOW"}, {"id": "M229", "name": "Aripiprazole", "asFound": "Association", "relevance": "HIGH"}, {"id": "M399", "name": "Quetiapine Fumarate", "asFound": "Sexual", "relevance": "HIGH"}, {"id": "M9312", "name": "Haloperidol", "relevance": "LOW"}, {"id": "M215475", "name": "Haloperidol decanoate", "relevance": "LOW"}, {"id": "M20999", "name": "Risperidone", "asFound": "Stable", "relevance": "HIGH"}, {"id": "M1675", "name": "Olanzapine", "asFound": "Cavity", "relevance": "HIGH"}, {"id": "M254665", "name": "Ziprasidone", "asFound": "Example", "relevance": "HIGH"}, {"id": "M8604", "name": "Fluphenazine", "relevance": "LOW"}, {"id": "M15512", "name": "Serotonin", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}, {"id": "M14474", "name": "Psychotropic Drugs", "relevance": "LOW"}, {"id": "M7473", "name": "Dopamine", "relevance": "LOW"}, {"id": "M20596", "name": "Dopamine Antagonists", "relevance": "LOW"}, {"id": "M17962", "name": "Dopamine Agents", "relevance": "LOW"}, {"id": "M4251", "name": "Antiemetics", "relevance": "LOW"}, {"id": "M8881", "name": "Gastrointestinal Agents", "relevance": "LOW"}, {"id": "M19649", "name": "Selective Serotonin Reuptake Inhibitors", "relevance": "LOW"}, {"id": "M4247", "name": "Antidepressive Agents", "relevance": "LOW"}, {"id": "M20595", "name": "Dopamine Agonists", "relevance": "LOW"}, {"id": "M29240", "name": "Serotonin 5-HT1 Receptor Agonists", "relevance": "LOW"}, {"id": "M19648", "name": "Serotonin Receptor Agonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "CNSDep", "name": "Central Nervous System Depressants"}, {"abbrev": "PsychDr", "name": "Psychotropic Drugs"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "AnDyAg", "name": "Anti-Dyskinesia Agents"}, {"abbrev": "AnEm", "name": "Antiemetics"}, {"abbrev": "Gast", "name": "Gastrointestinal Agents"}, {"abbrev": "CaAg", "name": "Cardiotonic Agents"}]}}, "hasResults": true}